Zogenix, Inc. (ZGNX): Price and Financial Metrics


Zogenix, Inc. (ZGNX): $26.68

0.42 (+1.60%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

ZGNX POWR Grades


  • Growth is the dimension where ZGNX ranks best; there it ranks ahead of 66.37% of US stocks.
  • ZGNX's strongest trending metric is Quality; it's been moving down over the last 177 days.
  • ZGNX's current lowest rank is in the Stability metric (where it is better than 1.97% of US stocks).

ZGNX Stock Summary

  • ZGNX's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 132 -- higher than 82.6% of US-listed equities with positive expected earnings growth.
  • ZGNX's price/sales ratio is 18.15; that's higher than the P/S ratio of 92.35% of US stocks.
  • As for revenue growth, note that ZGNX's revenue has grown 498.77% over the past 12 months; that beats the revenue growth of 98.34% of US companies in our set.
  • If you're looking for stocks that are quantitatively similar to Zogenix Inc, a group of peers worth examining would be KOPN, AIM, ACER, FORM, and GTHX.
  • Visit ZGNX's SEC page to see the company's official filings. To visit the company's web site, go to www.zogenix.com.

ZGNX Valuation Summary

  • ZGNX's price/earnings ratio is -3.4; this is 109.32% lower than that of the median Healthcare stock.
  • ZGNX's price/sales ratio has moved up 10.7 over the prior 130 months.
  • Over the past 130 months, ZGNX's EV/EBIT ratio has gone down 1.

Below are key valuation metrics over time for ZGNX.

Stock Date P/S P/B P/E EV/EBIT
ZGNX 2021-08-31 18.9 3.0 -3.4 -3.7
ZGNX 2021-08-30 18.6 3.0 -3.3 -3.6
ZGNX 2021-08-27 18.6 3.0 -3.3 -3.6
ZGNX 2021-08-26 18.2 2.9 -3.3 -3.5
ZGNX 2021-08-25 18.5 3.0 -3.3 -3.6
ZGNX 2021-08-24 18.2 2.9 -3.3 -3.5

ZGNX Growth Metrics

    Its 5 year price growth rate is now at 174.21%.
  • The year over year net income to common stockholders growth rate now stands at 41.67%.
  • Its 4 year price growth rate is now at 174.21%.
ZGNX's revenue has moved up $31,811,000 over the prior 67 months.

The table below shows ZGNX's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-09-30 63.585 -182.325 -242.7
2021-06-30 43.835 -180.539 -244.785
2021-03-31 26.078 -168.898 -239.213
2020-12-31 13.643 -167.531 -209.383
2020-09-30 7.09 -164.017 -195.273
2020-06-30 4.86 -153.562 -425.662

ZGNX's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • ZGNX has a Quality Grade of C, ranking ahead of 60.76% of graded US stocks.
  • ZGNX's asset turnover comes in at 0.071 -- ranking 291st of 681 Pharmaceutical Products stocks.
  • ARMP, BTX, and PRTK are the stocks whose asset turnover ratios are most correlated with ZGNX.

The table below shows ZGNX's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.071 0.944 -0.554
2021-03-31 0.042 0.953 -0.656
2020-12-31 0.022 0.960 -0.759
2020-09-30 0.013 0.980 -0.970
2020-06-30 0.010 1.000 -2.411
2020-03-31 0.010 1.000 -1.828

ZGNX Price Target

For more insight on analysts targets of ZGNX, see our ZGNX price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $41.00 Average Broker Recommendation 1.38 (Strong Buy)

ZGNX Stock Price Chart Interactive Chart >

Price chart for ZGNX

ZGNX Price/Volume Stats

Current price $26.68 52-week high $26.90
Prev. close $26.26 52-week low $11.03
Day low $26.51 Volume 11,252,300
Day high $26.90 Avg. volume 3,764,363
50-day MA $22.56 Dividend yield N/A
200-day MA $17.33 Market Cap 1.50B

Zogenix, Inc. (ZGNX) Company Bio


Zogenix develops and commercializes therapies for the treatment of central nervous system disorders. The company was founded in 2006 and is based in San Diego, California.


ZGNX Latest News Stream


Event/Time News Detail
Loading, please wait...

ZGNX Latest Social Stream


Loading social stream, please wait...

View Full ZGNX Social Stream

Latest ZGNX News From Around the Web

Below are the latest news stories about Zogenix Inc that investors may wish to consider to help them evaluate ZGNX as an investment opportunity.

Analysts Estimate Envestnet (ENV) to Report a Decline in Earnings: What to Look Out for

Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Entrepreneur.com | February 17, 2022

Zogenix (ZGNX) May Report Negative Earnings: Know the Trend Ahead of Q4 Release

Zogenix (ZGNX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Yahoo | February 17, 2022

Zogenix Supports New No-Cost Genetic Testing Program with United Mitochondrial Disease Foundation to Improve Diagnosis of Mitochondrial Diseases

Symptoms of mitochondrial diseases, such as Thymidine Kinase 2 deficiency (TK2d), can vary widely and mimic other rare and common diseases, making diagnosis challenging 1,2,3Genetic testing offers a quicker, confirmatory path to diagnosis, enabling more accurate care and participation in available clinical trials 1,2,3An estimated 1 in 5,000 individuals has a genetic mitochondrial disease 4 EMERYVILLE, Calif., Feb. 15, 2022 (GLOBE NEWSWIRE) -- Zogenix (NASDAQ: ZGNX), a global biopharmaceutical c

Yahoo | February 15, 2022

Why Zogenix Flew Higher Before Leveling Off This Week

Zogenix (NASDAQ: ZGNX) stock is having the ride of its life this week -- perhaps for the last time in its history. The biotech announced Wednesday it agreed to be acquired by Belgium-based pharmaceutical company UCB (OTC: UCBJF). The company's share price quickly rocketed higher, but it's basically stayed at the enhanced level.

Yahoo | January 21, 2022

Biotech Stock Roundup: ZGNX's Acquisition News, REGN, BLUE's Updates & More

Regulatory and other pipeline updates from Zogenix (ZGNX) and Regeneron (REGN) are among a few key highlights from the biotech sector during the past week.

Yahoo | January 20, 2022

Read More 'ZGNX' Stories Here

ZGNX Price Returns

1-mo N/A
3-mo 2.22%
6-mo 128.03%
1-year 49.64%
3-year -31.29%
5-year 110.91%
YTD 64.18%
2021 -18.71%
2020 -61.65%
2019 42.98%
2018 -8.96%
2017 229.63%

Continue Researching ZGNX

Want to see what other sources are saying about Zogenix Inc's financials and stock price? Try the links below:

Zogenix Inc (ZGNX) Stock Price | Nasdaq
Zogenix Inc (ZGNX) Stock Quote, History and News - Yahoo Finance
Zogenix Inc (ZGNX) Stock Price and Basic Information | MarketWatch

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7741 seconds.